skip to content

Clinical Trials

MainTitle

Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia

The recruitment status of this study is unknown.

Verified April 2000

Sponsor
Centaur Pharmaceuticals


Information provided by (Responsible Party)
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier
NCT00002414

First received: November 2, 1999
Last updated: June 23, 2005
Last Verified: April 2000
History of Changes
Purpose

Purpose

The purpose of this study is to see if it is safe and effective to give CPI-1189 to patients with AIDS dementia.

Advanced HIV infection can cause AIDS dementia (brain damage due to HIV leading to loss of memory and muscle control). CPI-1189 may be able to postpone AIDS dementia or slow it down.

Condition Intervention Phase
HIV Infections

Drug : CPI-1189
Phase 2

Study Type: Interventional
Study Design: Masking: Double
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Parallel Group, Placebo Controlled, Tolerability, Safety and Pilot Efficacy Study of CPI-1189 in HIV Infected Individuals With Cognitive and Motor Impairment

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Estimated Enrollment: 60

Detailed Description:

Late-stage HIV infection can cause AIDS dementia (brain damage due to HIV leading to loss of memory and muscle control). CPI-1189 may be able to postpone AIDS dementia or slow it down.
Patients are randomized to receive either placebo or one of two oral doses of CPI-1189 daily. Patients are assessed for safety and tolerability during Weeks 2, 6, and 10. At Week 10, efficacy assessments are also made. For those who volunteer, a sample of cerebrospinal fluid is obtained at baseline and at Week 10. Blood samples for CPI-1189 pharmacokinetic trough measurements are taken at Weeks 2 and 10. The open-label phase starts at Week 11. At Weeks 13 and 16, a safety evaluation is performed. At the end of the open-label phase, Week 22, a final set of safety and efficacy assessments and a blood sample for CPI-1189 pharmacokinetic trough measurement are obtained.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  

Criteria

Inclusion Criteria
You may be eligible for this study if you:

  • Are HIV-positive.
  • Are at least 18 years old.
  • Have symptoms of AIDS dementia including forgetfulness, loss of concentration, slow mental processing, or a loss of muscle control.
  • Have been on stable anti-HIV drug therapy for the past 6 weeks (if you are taking anti-HIV drugs).

  • Exclusion Criteria
    You will not be eligible for this study if you:
  • Have certain serious medical conditions, such as a mental disorder or an opportunistic
(AIDS-related) infection.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002414

Locations

United States, California
Alzheimers Disease Research Ctr 0948 / UCSD
San Diego, California, United States, 920930948
United States, Illinois
Northwestern Univ / Dept of Neurology
Chicago, Illinois, United States, 60611
United States, Maryland
Johns Hopkins Hosp / Dept of Neurology / Meyer 6109
Baltimore, Maryland, United States, 212877609
United States, Missouri
Washington Univ Sch of Med / Dept of Neurology
Saint Louis, Missouri, United States, 63110
United States, New York
Columbia Univ / Sergievsky Ctr Physicians and Surgeons
New York, New York, United States, 10032
Univ of Rochester / Strong Memorial Hosp
Rochester, New York, United States, 14620

Sponsors and Collaborators

Centaur Pharmaceuticals

Investigators

Study Chair: Clifford DB
More Information

More Information


Responsible Party: Centaur Pharmaceuticals  
ClinicalTrials.gov Identifier: NCT00002414   History of Changes  
Other Study ID Numbers: 289B  
  CPI001189-ADC01  
Study First Received: November 2, 1999  
Last Updated: June 23, 2005  

Keywords provided by NIH AIDS Clinical Trials Information Service:

AIDS Dementia Complex
Anti-HIV Agents

Additional relevant MeSH terms:
HIV Infections

ClinicalTrials.gov processed this data on October 16, 2017
This information is provided by ClinicalTrials.gov.